[
  {
    "ts": null,
    "headline": "Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC).1 These data were featured as a late-breaking oral presentation at the S",
    "url": "https://finnhub.io/api/news?id=5ebc759cb745ad1a82daa9ee31555facb6663538f68d25fc0fec9ec969d489ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764969600,
      "headline": "Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC",
      "id": 137715603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC).1 These data were featured as a late-breaking oral presentation at the S",
      "url": "https://finnhub.io/api/news?id=5ebc759cb745ad1a82daa9ee31555facb6663538f68d25fc0fec9ec969d489ba"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Maintains Johnson & Johnson (JNJ) Buy Recommendation",
    "summary": "Guggenheim Maintains Johnson & Johnson (JNJ) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=a39f18095ce6fb9599f5551d6841d6f946c2b3270fb1ee2e37ec85829b83112c",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764943632,
      "headline": "Guggenheim Maintains Johnson & Johnson (JNJ) Buy Recommendation",
      "id": 137695986,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a39f18095ce6fb9599f5551d6841d6f946c2b3270fb1ee2e37ec85829b83112c"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Races to Cut Its Risk From AI’s Borrowing Binge",
    "summary": "The urgency at banks to shed risk is visible all over credit markets.  The cost of protecting Oracle Corp. debt against default using derivatives has risen to the highest since the Global Financial Crisis.  Morgan Stanley has looked at using a significant risk transfer — a form of insurance against loan losses — to diffuse some of the risk tied to its tech company borrowers.",
    "url": "https://finnhub.io/api/news?id=b53eb934d8907f14b6e8428644fad1b49038c8e877893206c665f15693625de2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764934200,
      "headline": "Wall Street Races to Cut Its Risk From AI’s Borrowing Binge",
      "id": 137696882,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The urgency at banks to shed risk is visible all over credit markets.  The cost of protecting Oracle Corp. debt against default using derivatives has risen to the highest since the Global Financial Crisis.  Morgan Stanley has looked at using a significant risk transfer — a form of insurance against loan losses — to diffuse some of the risk tied to its tech company borrowers.",
      "url": "https://finnhub.io/api/news?id=b53eb934d8907f14b6e8428644fad1b49038c8e877893206c665f15693625de2"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
    "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
    "url": "https://finnhub.io/api/news?id=01405f7aafe79c82bd5dae021b1f3e9c1e4d74ba98213aea0d4cd18b20ef66d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764931320,
      "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
      "id": 137697022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
      "url": "https://finnhub.io/api/news?id=01405f7aafe79c82bd5dae021b1f3e9c1e4d74ba98213aea0d4cd18b20ef66d5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Johnson & Johnson on Max Dividends’s Substack. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson’s share was trading at $205.34 as of December 1st. JNJ’s trailing and forward P/E were 19.99 and 17.99 respectively according to Yahoo Finance. Johnson & Johnson (J&J) is a global […]",
    "url": "https://finnhub.io/api/news?id=48b55c02897fd5ba21e468ade6eb879e41762b0a6c89794d58c681a9002c9906",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764901546,
      "headline": "Johnson & Johnson (JNJ): A Bull Case Theory",
      "id": 137692352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Johnson & Johnson on Max Dividends’s Substack. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson’s share was trading at $205.34 as of December 1st. JNJ’s trailing and forward P/E were 19.99 and 17.99 respectively according to Yahoo Finance. Johnson & Johnson (J&J) is a global […]",
      "url": "https://finnhub.io/api/news?id=48b55c02897fd5ba21e468ade6eb879e41762b0a6c89794d58c681a9002c9906"
    }
  }
]